Shareholders meeting

25th June, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Bandra Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Proceedings of the 90th Annual General Meeting (‘AGM’) of the Company Dear Sir/Madam, We hereby inform that the 90th AGM of the Company was held on Thursday, 25th June, 2026 at 2.00 p.m. IST through video conferencing. Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing the following: 1. Speech by Dr Y K Hamied – Chairman 2. Presentation by Mr Achin Gupta – Managing Director and Global Chief Executive Officer 3. Proceedings of the AGM Kindly take the above on record. Thanking you, Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Encl: As above Prepared by: Simona Dsouza Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 Ninetieth Annual General Meeting Speech Address by Dr Y K Hamied, Chairman, Cipla Limited on 25th June 2026 Dear Shareholders, Welcome to the 90th Annual General Meeting of your Company. We concluded another eventful year at Cipla, completing 90 years since Dr K A Hamied, our Founder, started the Company in 1935. Reflecting on this journey, one is reminded of our Founder’s enduring belief that scientific progress must essentially serve society and humanity. This has guided Cipla through many decades of change and continues to define our approach to ‘Caring for Life’. My own association with Cipla started in 1960 and spans seven decades. It has been a privilege to witness Cipla’s growth and development, from a Company built on limited indigenous capability into a global organisation serving patients across the world. Our direction has always remained clear, to expand access to affordable medicines, strengthen R&D and scientific capability, address healthcare needs in a responsible and meaningful manner, and ensure that none should be denied medication. During the last financial year, Cipla’s performance has maintained our position as a leading Indian pharma company. We have a presence across a number of key markets and therapeutic areas. Our manufacturing and marketing capabilities reflect our position as a trusted and reliable partner. This, over the years, has been achieved through a consistent emphasis on maintaining excellent quality, improving scientific innovation and manufacturing strength. Success is not the destination that one reaches. Success is the quality of the journey. The overall achievement of a company cannot be measured by monetary gain but by the capacity and capability to contribute towards the moral and social obligations of society. For the last 90 years, Cipla has focused on making medicines accessible, particularly to those in need, especially in India and Africa. An example of this was Cipla’s pioneering response to the HIV/AIDS crisis in Africa during the early part of this century. We believe that our initiative resulted in saving millions of lives. Our efforts are ongoing to control diseases such as this, malaria, TB and parasitic infections. This year, our Cipla Palliative Care Hospital in Pune will complete 29 years. It is the first centre of its kind in India and perhaps anywhere in the world. It portrays Cipla’s philosophy and reflects our ongoing commitment to care beyond treatment. Over the years, this centre has provided comfort, relief, dignity, and support to thousands of patients and their families. We are gradually expanding this support system which will benefit palliative care services throughout India. Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 We celebrated Cipla’s 90-year journey during the year. Cipla launched a comic book for children, which covers the Cipla Story that shows our value to the younger generation. The Government of India also recognised Cipla’s contribution to public health by issuing a special commemorative stamp to mark our 90th year. Apart from this, Cipla introduced a virtual tour of its journey on our website (virtualtour.cipla.com) whereby a wide audience can participate in our history and legacy. This will continue to guide and inspire future generations. Looking ahead, there is a clear responsibility that we must follow. Healthcare needs to evolve on a continuous basis, and access remains a major issue across many parts of the world, which we have to tackle. Cipla will always continue to respond with focus and discipline and remain true to its purpose of providing access to affordable quality medicines. We are delivering a meaningful impact in the world of medicine guided by scientific progress and catering to patient needs. One of the strengths of Cipla continues to be its people. Today, with a global workforce of around 31,000, there is a shared sense of purpose that binds us all together. It involves commitment, integrity, honesty and belief which uphold Cipla’s values that will sustain us in the future. We would like to thank two Board Members who have completed their tenure, Mr Vohra, and Mr Stewart, for their contribution and wish them the very best in the years ahead. I am pleased to welcome Mr P R Ramesh our Lead Independent Director as Vice-Chairman of our Company. His experience and association with the Board have been invaluable and he will continue to assist Cipla as we have entered the next decade. We also welcome Mr Achin Gupta as our Managing Director and Global CEO. Apart from this, my sincere thanks to the medical profession, all our local and international partners, as also those who work along with us to ensure patients’ needs are met with care. Above all, I would like to thank you, our shareholders, for your continued trust, support and confidence in Cipla. We are moving forward towards our century in 2035. This milestone will be an ongoing responsibility, which we have to face with integrity and commitment to continue our progress in Caring for Life. We will maintain the legacy of our mission into the next century. We are confident that Cipla will uphold its values and continue to contribute meaningfully to improving the quality of life of our fellow men in the years ahead. Thank you. Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 CLICK TO EDIT MASTER TITLE STYLE CLICK HERE TO ADD TITLE Click here to add subtitle Click here to copy here Annual General Meeting MD & GCEO’s Address Achin Gupta June 2026 Highest-ever Yearly Revenue Despite Multiple Headwinds Revenue EBITDA PAT 21.0% INR 3,879 Cr 13.8% INR 28,163 Cr INR 5,925 Cr FY26 Margin Margin Business Performance Snapshot Emerging Markets & One India North America One Africa Europe INR 12,680 Cr 9% $ 780 Mn $ 483 Mn 7% $ 405 Mn (YoY) (YoY) FY26 Delivered double-digit Received approval for the SA private growing at a Crossed $ 400 Mn growth across 3 segments first AB-rated gVentolin market1 growth multiple of benchmark in Q4 FY26 with CGT 1.4x 1.MarketdataasperIQVIAMATFeb’26 2 Building scale with Financial Discipline Strong $1Bn+ Net Cash position Revenue1 ToTtoatallC Caasshh21 28,163 27,548 11,140 10,807 25,455 22,334 21,763 8,267 6,273 4,965 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 614 Cr. R&D4 Expense Total Debt3 % of revenue [Showing first 8,000 characters — download PDF for full document]